



Dr John Holaday, Successful Biotech Entrepreneur and Industry Expert, to Join Neuren's Board of Directors

SYDNEY, Australia, 25 November 2009: Robin Congreve, Chairman of Neuren Pharmaceuticals (ASX:NEU) is pleased to announce today that Dr John Holaday has agreed to serve on its Board of Directors. On welcoming Dr Holaday to the Board Dr Congreve said that the Board and Neuren would be significantly strengthened by his 40 years of experience as a scientist, executive manager of biotechnology and biopharmaceutical companies, and banker.

Dr Holaday is currently CEO of QRxPharma, a listed specialty pharmaceutical company specializing in pain and CNS diseases (ASX:QRX; OTCQX:QRXPY). Dr Holaday, a veteran life-science entrepreneur, has built five public and private biopharmaceutical companies over the past 21 years and raised more than US\$450 million in capital. Dr Holaday founded EntreMed (NASDAQ: ENMD, NASDAQ) in 1992 and served as its Chairman, President and CEO until his retirement in 2003 and was the co-founder, director, Scientific Director and SVP of Medicis Pharmaceutical Corporation (NYSE: MRX). He was the founder and Chief of the Neuropharmacology Branch at the Walter Reed Army Institute of Research for 21 years.

Dr Holaday has received numerous honors and awards, including induction into Ernst and Young's Entrepreneur of the Year 2006 Hall of Fame. He holds over 60 U.S. and foreign patents, has published more than 200 scientific articles and reviews, and edited five books.

Commenting on his appointment to Neuren's Board, Dr Holaday said: "I am delighted to be joining Neuren's Board and look forward to working with the other directors and management on the critically important work that the Company is undertaking. Neuren is a leader in the development of drugs for the treatment of CNS injury and ischemia and recently received a multi-million dollar grant from the US Army to advance their lead product. This is an area of research that I know well and I am pleased to be part of this board. I am confident that the quality of the science generated by Neuren and the US Army and their innovative clinical development strategy will provide a solid foundation from which to advance their critically needed drug to treat traumatic brain injuries."

"I look forward to working with John again, as we have been friends and colleagues for many years," said Larry Glass, CEO of Neuren. "His knowledge and expertise in the scientific, regulatory and capital market environments will no doubt be of great value to us as we progress our product portfolio."



About Neuren

Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapeutics in the fields of brain injury, neurological diseases and conditions, and cancer. The Neuren portfolio comprises seven product families targeting markets with large unmet needs and limited competition. Neuren has two clinical-stage molecules — Motiva™ and NNZ-2566 — focused on a range of acute and chronic neurological conditions as well as a number of drug discovery programs focused on important targets in neurology and, through its subsidiary Perseis Therapeutics Limited, oncology. For more information, please visit www.neurenpharma.com.

For more information, contact:

Larry Glass, CEO Tel : +1 301 758 2987